{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:38:18Z","timestamp":1790563098271,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100019436","name":"PanKind Australian Pancreatic Cancer Foundation Limited","doi-asserted-by":"publisher","award":["RG172336"],"award-info":[{"award-number":["RG172336"]}],"id":[{"id":"10.13039\/501100019436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023175","name":"Illawarra Cancer Carers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023175","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1100432"],"award-info":[{"award-number":["APP1100432"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1053\/j.gastro.2025.07.021","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T23:55:46Z","timestamp":1753919746000},"page":"89-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Selective Urokinase Inhibition Plus Chemotherapy: A Novel Approach to Pancreatic Cancer Treatment via Enhanced Antitumor Immunity and Decreased Metastasis"],"prefix":"10.1053","volume":"170","author":[{"given":"S.M.","family":"Zahid Hosen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashna A.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpha Raj","family":"Mekapogu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamini","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Pirola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Kelso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Ranson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoti","family":"Apte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2025.07.021_bib1","series-title":"Pancreatic cancer in Australia statistics","year":"2024"},{"key":"10.1053\/j.gastro.2025.07.021_bib2","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1586\/era.10.148","article-title":"Challenges of drug resistance in the management of pancreatic cancer","volume":"10","author":"Sheikh","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1053\/j.gastro.2025.07.021_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju413","article-title":"nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial","volume":"107","author":"Goldstein","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.gastro.2025.07.021_bib4","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.gastro.2025.07.021_bib5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00280-020-04051-x","article-title":"Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer","volume":"85","author":"Keum","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.gastro.2025.07.021_bib6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/MPA.0000000000001234","article-title":"The benefit-risk balance of Nab-paclitaxel in metastatic pancreatic adenocarcinoma","volume":"48","author":"P\u00e9ron","year":"2019","journal-title":"Pancreas"},{"key":"10.1053\/j.gastro.2025.07.021_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1053\/j.gastro.2025.07.021_bib8","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2217\/imt-2019-0164","article-title":"Is immunotherapy the holy grail for pancreatic cancer?","volume":"11","author":"Andersson","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1053\/j.gastro.2025.07.021_bib9","doi-asserted-by":"crossref","first-page":"6775","DOI":"10.3748\/wjg.v27.i40.6775","article-title":"Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer","volume":"27","author":"Ostios-Garcia","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.07.021_bib10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.gastro.2025.07.021_bib11","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.aam7622","article-title":"Drugging RAS: know the enemy","volume":"355","author":"Papke","year":"2017","journal-title":"Science"},{"key":"10.1053\/j.gastro.2025.07.021_bib12","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.gastro.2025.07.021_bib13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/biom12020152","article-title":"The urokinase plasminogen activation system in pancreatic cancer: prospective diagnostic and therapeutic targets","volume":"12","author":"Kumar","year":"2022","journal-title":"Biomolecules"},{"key":"10.1053\/j.gastro.2025.07.021_bib14","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1038\/onc.2017.63","article-title":"SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer","volume":"36","author":"Harris","year":"2017","journal-title":"Oncogene"},{"key":"10.1053\/j.gastro.2025.07.021_bib15","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1001\/jamasurg.2019.3337","article-title":"Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial","volume":"154","author":"Jones","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1053\/j.gastro.2025.07.021_bib16","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/bjs.11295","article-title":"Meta-analysis of recurrence pattern after resection for pancreatic cancer","volume":"106","author":"Tanaka","year":"2019","journal-title":"Br J Surg"},{"key":"10.1053\/j.gastro.2025.07.021_bib17","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.hpb.2020.01.005","article-title":"Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study","volume":"22","author":"Kalisvaart","year":"2020","journal-title":"HPB (Oxford)"},{"key":"10.1053\/j.gastro.2025.07.021_bib18","doi-asserted-by":"crossref","first-page":"248","DOI":"10.14701\/ahbps.23-149","article-title":"Prognostication for recurrence patterns after curative resection for pancreatic ductal adenocarcinoma","volume":"28","author":"Ang","year":"2024","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"10.1053\/j.gastro.2025.07.021_bib19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrc2400","article-title":"Revisiting the biological roles of PAI2 (SERPINB2) in cancer","volume":"8","author":"Croucher","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.gastro.2025.07.021_bib20","doi-asserted-by":"crossref","DOI":"10.21037\/apc.2019.05.02","article-title":"Multifunctional role of pancreatic stellate cells in pancreatic cancer","volume":"2","author":"Mekapogu","year":"2019","journal-title":"Annals of Pancreatic Cancer"},{"key":"10.1053\/j.gastro.2025.07.021_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/1177271917715443","article-title":"Prognostic impact of urokinase plasminogen activator receptor expression in pancreatic cancer: malignant versus stromal cells","volume":"12","author":"de Geus","year":"2017","journal-title":"Biomark Insights"},{"key":"10.1053\/j.gastro.2025.07.021_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1060957","article-title":"Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: key role of the urokinase plasminogen activator (PLAU)","volume":"13","author":"Hosen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1053\/j.gastro.2025.07.021_bib23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s12551-021-00921-7","article-title":"Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human\/mouse species selectivity","volume":"14","author":"El Salamouni","year":"2022","journal-title":"Biophys Rev"},{"key":"10.1053\/j.gastro.2025.07.021_bib24","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1021\/acs.molpharmaceut.3c00055","article-title":"Recent advances in targeting the urokinase plasminogen activator with nanotherapeutics","volume":"20","author":"Kumar","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1053\/j.gastro.2025.07.021_bib25","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/bjc.2013.62","article-title":"Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer","volume":"108","author":"Heinemann","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1053\/j.gastro.2025.07.021_bib26","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/13543784.2023.2284385","article-title":"Upamostat: a serine protease inhibitor for antiviral, gastrointestinal, and anticancer indications","volume":"32","author":"Plasse","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1053\/j.gastro.2025.07.021_bib27","doi-asserted-by":"crossref","first-page":"8299","DOI":"10.1021\/acs.jmedchem.8b00838","article-title":"6-Substituted hexamethylene amiloride (HMA) derivatives as potent and selective inhibitors of the human urokinase plasminogen activator for use in cancer","volume":"61","author":"Buckley","year":"2018","journal-title":"J Med Chem"},{"key":"10.1053\/j.gastro.2025.07.021_bib28","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3390\/biom12091309","article-title":"6-Furopyridine hexamethylene amiloride is a non-selective P2X7 receptor antagonist","volume":"12","author":"Cuthbertson","year":"2022","journal-title":"Biomolecules"},{"key":"10.1053\/j.gastro.2025.07.021_bib29","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1021\/acs.molpharmaceut.2c01083","article-title":"Automated patch clamp screening of amiloride and 5-N, N-hexamethyleneamiloride analogs identifies 6-iodoamiloride as a potent acid-sensing ion channel inhibitor","volume":"20","author":"Finol-Urdaneta","year":"2023","journal-title":"Mol Pharmaceut"},{"key":"10.1053\/j.gastro.2025.07.021_bib30","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.3390\/ijms22062999","article-title":"Screening of 5- and 6-substituted amiloride libraries identifies dual-uPA\/NHE1 active and single target-selective inhibitors","volume":"22","author":"Buckley","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.gastro.2025.07.021_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116116","article-title":"Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride","volume":"37","author":"Buckley","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1053\/j.gastro.2025.07.021_bib32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/bjc.2015.478","article-title":"Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer","volume":"114","author":"Pothula","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1053\/j.gastro.2025.07.021_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216286","article-title":"HGF\/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis","volume":"568","author":"Mekapogu","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1053\/j.gastro.2025.07.021_bib34","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/s41416-020-0782-1","article-title":"Targeting the HGF\/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis","volume":"122","author":"Xu","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1053\/j.gastro.2025.07.021_bib35","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1073\/pnas.72.7.2662","article-title":"Solid tumor models for the assessment of different treatment modalities: I. Radiation-induced changes in growth rate characteristics of a solid tumor model","volume":"72","author":"Looney","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2025.07.021_bib36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1634\/stemcells.2006-0243","article-title":"In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models","volume":"25","author":"Meyerrose","year":"2007","journal-title":"Stem Cells"},{"key":"10.1053\/j.gastro.2025.07.021_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/1878-0261.13552","article-title":"Plasminogen deficiency suppresses pancreatic ductal adenocarcinoma disease progression","volume":"18","author":"Chowdhury","year":"2024","journal-title":"Mol Oncol"},{"key":"10.1053\/j.gastro.2025.07.021_bib38","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2353\/ajpath.2010.090899","article-title":"Role of pancreatic stellate cells in pancreatic cancer metastasis","volume":"177","author":"Xu","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1053\/j.gastro.2025.07.021_bib39","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1053\/j.gastro.2012.11.037","article-title":"A starring role for stellate cells in the pancreatic cancer microenvironment","volume":"144","author":"Apte","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.07.021_bib40","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/MOG.0000000000000196","article-title":"Pancreatic stellate cell: physiologic role, role in fibrosis and cancer","volume":"31","author":"Apte","year":"2015","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1053\/j.gastro.2025.07.021_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.612271","article-title":"Stroma involvement in pancreatic ductal adenocarcinoma: an overview focusing on extracellular matrix proteins","volume":"12","author":"Liot","year":"2021","journal-title":"Front Immunol"},{"key":"10.1053\/j.gastro.2025.07.021_bib42","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.15252\/embr.201439246","article-title":"The extracellular matrix modulates the hallmarks of cancer","volume":"15","author":"Pickup","year":"2014","journal-title":"EMBO Rep"},{"key":"10.1053\/j.gastro.2025.07.021_bib43","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.trecan.2019.01.001","article-title":"Targeting pancreatic stellate cells in cancer","volume":"5","author":"Schnittert","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1053\/j.gastro.2025.07.021_bib44","doi-asserted-by":"crossref","first-page":"E3769","DOI":"10.1073\/pnas.1722434115","article-title":"Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk","volume":"115","author":"Orozco","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2025.07.021_bib45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.canlet.2017.03.024","article-title":"Galectin-1-driven upregulation of SDF-1 in pancreatic stellate cells promotes pancreatic cancer metastasis","volume":"397","author":"Qian","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1053\/j.gastro.2025.07.021_bib46","doi-asserted-by":"crossref","first-page":"86488","DOI":"10.18632\/oncotarget.21212","article-title":"PSC-derived Galectin-1 inducing epithelial-mesenchymal transition of pancreatic ductal adenocarcinoma cells by activating the NF-\u03baB pathway","volume":"8","author":"Tang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.gastro.2025.07.021_bib47","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/stmcls\/sxad017","article-title":"Metabolic rewiring and stemness: a critical attribute of pancreatic cancer progression","volume":"41","author":"Ogunleye","year":"2023","journal-title":"Stem Cells"},{"key":"10.1053\/j.gastro.2025.07.021_bib48","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1091\/mbc.e12-04-0306","article-title":"Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer","volume":"24","author":"Asuthkar","year":"2013","journal-title":"Mol Biol Cell"},{"key":"10.1053\/j.gastro.2025.07.021_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-09946-z","article-title":"ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer","volume":"7","author":"Gharibi","year":"2017","journal-title":"Sci Rep"},{"key":"10.1053\/j.gastro.2025.07.021_bib50","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/MPA.0000000000000373","article-title":"Retinoic acid reduces stem cell\u2013like features in pancreatic cancer cells","volume":"44","author":"Herreros-Villanueva","year":"2015","journal-title":"Pancreas"},{"key":"10.1053\/j.gastro.2025.07.021_bib51","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1016\/j.cell.2021.08.023","article-title":"Proteogenomic characterization of pancreatic ductal adenocarcinoma","volume":"184","author":"Cao","year":"2021","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2025.07.021_bib52","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3390\/cancers14040995","article-title":"The immune landscape of human pancreatic ductal carcinoma: key players, clinical implications, and challenges","volume":"14","author":"Muller","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.gastro.2025.07.021_bib53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s13402-022-00741-1","article-title":"Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment","volume":"46","author":"Zhu","year":"2023","journal-title":"Cell Oncol (Dordr)"},{"key":"10.1053\/j.gastro.2025.07.021_bib54","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1158\/1078-0432.CCR-16-2318","article-title":"Strategies for increasing pancreatic tumor immunogenicity","volume":"23","author":"Johnson","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2025.07.021_bib55","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1182\/blood-2008-08-176438","article-title":"Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1\/sec","volume":"113","author":"Ilkovitch","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.gastro.2025.07.021_bib56","first-page":"4263","article-title":"uPA and uPA-receptor are involved in cancer-associated myeloid-derived suppressor cell accumulation","volume":"32","author":"Ilkovitch","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1053\/j.gastro.2025.07.021_bib57","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ijc.1330","article-title":"TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system","volume":"93","author":"Ellenrieder","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1053\/j.gastro.2025.07.021_bib58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.exer.2013.06.020","article-title":"TGF-\u03b22 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression","volume":"115","author":"Sugioka","year":"2013","journal-title":"Exp Eye Res"},{"key":"10.1053\/j.gastro.2025.07.021_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154062","article-title":"Urokinase plasminogen activator induces epithelial-mesenchymal and metastasis of pancreatic cancer through plasmin\/MMP14\/TGF-\u03b2 axis, which is inhibited by 4-acetyl-antroquinonol B treatment","volume":"100","author":"Wu","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1053\/j.gastro.2025.07.021_bib60","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.canlet.2015.10.035","article-title":"Key role of pancreatic stellate cells in pancreatic cancer","volume":"381","author":"Pothula","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1053\/j.gastro.2025.07.021_bib61","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3892\/ijo.2012.1516","article-title":"Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells","volume":"41","author":"Duong","year":"2012","journal-title":"Int J Oncol"},{"key":"10.1053\/j.gastro.2025.07.021_bib62","article-title":"Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs)","volume":"12","author":"Wang","year":"2017","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2025.07.021_bib63","doi-asserted-by":"crossref","first-page":"9170","DOI":"10.3390\/ijms21239170","article-title":"Targeting HGF\/c-MET axis in pancreatic cancer","volume":"21","author":"Pothula","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.gastro.2025.07.021_bib64","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1002\/j.1460-2075.1992.tb05588.x","article-title":"Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor\/scatter factor","volume":"11","author":"Naldini","year":"1992","journal-title":"EMBO J"},{"key":"10.1053\/j.gastro.2025.07.021_bib65","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1006\/bbrc.1994.1164","article-title":"Purification and characterization of hepatocyte growth factor (HGF)-converting enzyme: activation of pro-HGF","volume":"198","author":"Mizuno","year":"1994","journal-title":"Biochem Biophys Res Comm"},{"key":"10.1053\/j.gastro.2025.07.021_bib66","first-page":"949","article-title":"Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA","volume":"143","author":"Mars","year":"1993","journal-title":"Am J Pathol"},{"key":"10.1053\/j.gastro.2025.07.021_bib67","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/carcin\/bgu122","article-title":"The role of the hepatocyte growth factor\/c-MET pathway in pancreatic stellate cell\u2013endothelial cell interactions: antiangiogenic implications in pancreatic cancer","volume":"35","author":"Patel","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1053\/j.gastro.2025.07.021_bib68","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1158\/0008-5472.CAN-05-0946","article-title":"Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-i receptor\u2013mediated migration and invasion and orthotopic tumor growth in mice","volume":"65","author":"Bauer","year":"2005","journal-title":"Cancer Res"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508525057762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508525057762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T13:02:13Z","timestamp":1779541333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508525057762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0016508525057762"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2025.07.021","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective Urokinase Inhibition Plus Chemotherapy: A Novel Approach to Pancreatic Cancer Treatment via Enhanced Antitumor Immunity and Decreased Metastasis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2025.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the AGA Institute.","name":"copyright","label":"Copyright"}]}}